USANA Health Sciences: Strong Moat, Highly Profitable And Growing Sales


  • Founded by a world-class scientist while marketing its products via Olympians, Dr. Oz., and strong sales associates, USANA created the entrenched moats of brand recognition and product awareness.
  • With increasing expansion into the vast Asian markets, the firm is well positioned for continuing sales growth.
  • As the world population is aging, there is an increasing demand for personal wellness products to service degenerative diseases.
  • Despite operating a highly profitable business, the company is on sales as indicated by the mouthwatering P/E of 17.


According to research at the National Institute of Health, global life expectancy is projected to increase by almost eight years (from 68.6 years in 2015 to 76.2 years in 2050). Moreover, the number of people aged 80 and older (in some Asian and Latin America countries) are expected to increase as much as four fold by the same year. With the aging world population comes the rising demand for personal wellness products (aka herbal/dietary supplements) to service the degenerative diseases (like osteoarthritis or the usual "wear and tear") that come with aging. That being said, USANA Health Sciences (NYSE:USNA), a firm based in Salt Lake City, Utah, is poised to capture this niche of growing demand.

Source: Google Finance

And with the recent completion of its China manufacturing facility, USANA is gearing up for continuing its explosive growth in the Asia-Pacific regions. Of note, the Asian demographics tend to consume more herbal supplements than elsewhere in the world due to their cultural receptiveness toward complementary and alternative medicine. As a result, the oriental environment created the highly favorable market (and reinforced the entrenched moat) for USANA's business operations.

Low Costs/Less Regulatory Oversees

In contrast to a developmental-stage biopharma (that usually incurs approximately $1B to innovate a therapeutic from bench research to commercialization in a decade-long process), firms selling supplements like USANA have key advantages. Notably, there are no strict regulatory hurdles that can hamper corporate growth. Hence, the company is not required to run its products through the time-consuming and cost-burdening process of clinical studies (that are requisites for a biotech firm).

Aside from the minor manufacturing and other quality measures, USANA has very few regulatory constraints. Accordingly, the firm can rapidly launch its products with just the following compliance label:

"These statements have not been evaluated by the

This article was written by

BioSci Capital Partners profile picture
Become an Expert Bio-Investor with the Columbia Doc/Scientist/Market Whiz

Founded by Dr. Harvey Tran MD, MS, CNPR, (in collaboration with other PhDs), Integrated BioSci Investing LLC (“IBI) is a growing community of experts and everyday investors who help one another to invest better.

We bring to you a NEW investment philosophy called “Integrated BioSci Investing.” It's a distillation of value/growth investing wisdom from gurus such as Warren Buffett, Buffet's mentors (Ben Graham and Phil Fischer), and Sir John Templeton that are adapted specifically for biotech stocks.

IBI's analytical research is powered by the integration of (medical, scientific, and market) expertise to deliver unprecedented accuracy in clinical trial forecasting that, in and of itself, is one of the requisites to finding alpha bioscience investment.

Ultimately, our tireless due diligence and the wisdom of IBI members translate into strong returns for you. To name a couple of winners, Crispr Therapeutics (CRSP), CryoPort (CYRX), and Guardant Health (GH), correspondingly delivered 679.1%, 778.3%, and +435.9% for our subscribers."

As an IBI member, you’ll enjoy the following EXCLUSIVE benefits: daily real-time research articles that are comprehensive and more in-depth than free research articles; access to the chat room with many experts and everyday investors for you to ask your questions live about your favorite stocks (you’re expected to get an answer no later than 24 hours); ability to view our high performing portfolios and their pertinent updates; consulting on strategies to help you set up your own portfolios; Our best ideas and their updates via a research article or chat; potential to have research featured on your favorite companies; ability to reach Dr. Tran via phone call or Skype as you wish.

CLICK the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs.

CONNECT with Dr. Tran through his LinkedTree

READ more on (and make sure to register for our mailing list).

LEARN about Dr. Tran’s background in an in-depth article by following this link.

"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (9)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.